Navigation Links
Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD
Date:10/31/2007

HENNIGSDORF and BERLIN, Germany, October 31 /PRNewswire/ -- Revotar Biopharmaceuticals AG., today announced first positive results from an investigator driven open labelled Phase IIa pilot study in 14 patients with stable COPD stage 0 to II (GOLD criteria) inhaling 70 mg of Bimosiamose twice a day. The study was conducted at the Charite - Medical School Charite Berlin, Prof. Witt and the Respiratory Institute Wiesbaden, Dr. Beeh. The results were presented during the recent European Respiratory Society Meeting in Stockholm in September.

"Despite of the short treatment period we were surprised to see that analysis of induced sputum prior to and after Bimosiamose treatment of 9 days showed that both relative and absolute lymphocytes count decreased significantly. In addition, sputum IL-8 was significantly decreased. The latter is supposed to correlate with the severity of the disease," commented Prof. Dr. Meyer-Sabellek, clinical advisor to Revotar and previously SVP Research&Development at AstraZeneca, Germany. "Inhalation of Bimosiamose twice daily for up to 9 days was well tolerated and safe in patients. This targeted therapy provides the potential to prevent the further progression of inflammatory components in COPD and should be evaluated further in larger clinical trials," added Prof. Dr. Witt from the Charite and the Principal Investigator of the study.

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises many serious conditions affecting the lung. More than 30 million people are living with COPD worldwide. COPD is the fourth leading cause of death and is responsible for more than 120,000 deaths a year in the US and Western Europe alone. The disease costs the US healthcare system US$40 billion per year.

About Revotar Biopharmaceutical AG

Revotar develops innovative anti-inflammatory drugs for inflammatory indications such as psoriasis, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Bimosiamose has already passed several clinical Phase I and Phase IIa trials in asthma and psoriasis with a good safety and efficacy profile in over 140 human beings. In summer 2006 Revotar announced the signing of a Start-Up Development Agreement with a US Pharma company for the further development of Bimosiamose in one major disease area. Revotar will present during the BioEurope conference in Hamburg on November 14, 2007.

Contact Address:

Stephan Tarlach

Executive Board

Revotar Biopharmaceuticals AG

Neuendorfstr. 24a

D-16761 Hennigsdorf

phone: +49-3302-2025040

fax: +49-3302-2025030

e-mail: s.tarlach@revotar-ag.de

http://www.revotar.de


'/>"/>
SOURCE Revotar Biopharmaceutics AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... CT (PRWEB) , ... July 25, 2017 , ... ... products that enhance the microbiome and improve efficiency of livestock farming while reducing ... that it has licensed additional intellectual property from Cornell University. , These ...
(Date:7/24/2017)... ... July 24, 2017 , ... Each year, Inavero’s Best ... proven their superior service quality as rated by hiring professionals and job candidates. ... based on service quality ratings from their placed talent. , Fewer than 2% ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture ... the company’s board of directors. This addition continues to strengthen and diversify VIC’s ... Goforth, CEO and Chairman. “He is a highly accomplished business executive with a broad ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):